JP2010514817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514817A5 JP2010514817A5 JP2009544404A JP2009544404A JP2010514817A5 JP 2010514817 A5 JP2010514817 A5 JP 2010514817A5 JP 2009544404 A JP2009544404 A JP 2009544404A JP 2009544404 A JP2009544404 A JP 2009544404A JP 2010514817 A5 JP2010514817 A5 JP 2010514817A5
- Authority
- JP
- Japan
- Prior art keywords
- saccharide
- protein carrier
- protein
- aliquot
- carbodiimide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 150000001720 carbohydrates Chemical class 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 17
- 150000001718 carbodiimides Chemical class 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 9
- 230000021615 conjugation Effects 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 2
- 101710197219 Alpha-toxin Proteins 0.000 claims 2
- -1 MRPII Proteins 0.000 claims 2
- 101710124951 Phospholipase C Proteins 0.000 claims 2
- 240000005499 Sasa Species 0.000 claims 2
- 239000002776 alpha toxin Substances 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101710154607 Azurocidin Proteins 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 101000822677 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein 1 Proteins 0.000 claims 1
- 101000822695 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein C1 Proteins 0.000 claims 1
- 101710105699 D-alanyl-D-alanine carboxypeptidase DacB Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 claims 1
- 101710141457 Histidine-binding periplasmic protein Proteins 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- 101710087657 Manganese ABC transporter substrate-binding lipoprotein Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 101710167890 Penicillin-binding protein 4 Proteins 0.000 claims 1
- 241000404883 Pisa Species 0.000 claims 1
- 101710092628 Probable histidine-binding protein Proteins 0.000 claims 1
- 101000576806 Protobothrops flavoviridis Small serum protein 1 Proteins 0.000 claims 1
- 101000576807 Protobothrops flavoviridis Small serum protein 2 Proteins 0.000 claims 1
- 101710202103 Putative beta-lactamase HcpD Proteins 0.000 claims 1
- 108091030066 RNAIII Proteins 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010064033 elastin-binding proteins Proteins 0.000 claims 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102220117512 rs886041928 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700136.5 | 2007-01-04 | ||
| GBGB0700136.5A GB0700136D0 (en) | 2007-01-04 | 2007-01-04 | Process for manufacturing vaccines |
| PCT/EP2008/050011 WO2008081014A2 (en) | 2007-01-04 | 2008-01-02 | Process for manufacturing vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514817A JP2010514817A (ja) | 2010-05-06 |
| JP2010514817A5 true JP2010514817A5 (enExample) | 2011-02-10 |
| JP5683815B2 JP5683815B2 (ja) | 2015-03-11 |
Family
ID=37801736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544404A Expired - Fee Related JP5683815B2 (ja) | 2007-01-04 | 2008-01-02 | ワクチンの製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8858955B2 (enExample) |
| EP (1) | EP2099487B1 (enExample) |
| JP (1) | JP5683815B2 (enExample) |
| CA (1) | CA2674007A1 (enExample) |
| ES (1) | ES2546186T3 (enExample) |
| GB (1) | GB0700136D0 (enExample) |
| WO (1) | WO2008081014A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12302A (en) * | 2000-06-29 | 2003-10-24 | Glaxosmithkline Biolog Sa | Multivalent vaccine composition. |
| WO2002020059A2 (en) * | 2000-09-01 | 2002-03-14 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Vibrio cholerae o139 conjugate vaccines |
| US9486515B2 (en) | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
| AU2008292897B2 (en) | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| EP2376526A4 (en) | 2008-12-24 | 2013-02-27 | Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M | MODIFIED STREPTOCOCCUS PNEUMONIAE PNEUMOLYSIN (PLY) POLYPEPTIDE |
| PT3281947T (pt) | 2009-04-03 | 2020-05-07 | Univ Chicago | Composições e métodos relacionados com variantes da proteína a (spa) |
| WO2010119343A2 (en) * | 2009-04-14 | 2010-10-21 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| WO2011008548A1 (en) | 2009-06-29 | 2011-01-20 | Genocea Biosciences, Inc. | Vaccines and compositions against streptococcus pneumoniae |
| MX345967B (es) * | 2009-10-30 | 2017-02-28 | Novartis Ag | Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8. |
| US9649372B2 (en) | 2009-12-22 | 2017-05-16 | Sanofi Pasteur Limited | Immunogenic compositions and related methods |
| EP2588120B1 (en) | 2010-07-02 | 2017-11-15 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
| MX344120B (es) | 2011-01-20 | 2016-12-06 | Genocea Biosciences Inc | Vacunas y composiciones contra streptococcus pneumoniae. |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| HRP20201127T1 (hr) | 2012-04-26 | 2020-11-27 | University Of Chicago | Antigeni stafilokokne koagulaze i metode primjene istih |
| KR20170030635A (ko) | 2014-07-18 | 2017-03-17 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 바이러스 유사 입자를 포함하는 백신 |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10881723B2 (en) | 2016-01-15 | 2021-01-05 | Km Biologics Co., Ltd. | Vaccine containing immobilized virus particles |
| US11214600B2 (en) * | 2016-02-12 | 2022-01-04 | The University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease |
| AU2017321863B2 (en) | 2016-09-02 | 2024-07-11 | Sanofi Vaccines US Inc. | Neisseria meningitidis vaccine |
| DK3562503T3 (da) | 2016-12-30 | 2025-05-26 | Vaxcyte Inc | Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| BR112021022902A2 (pt) | 2019-05-14 | 2022-01-25 | Univ Chicago | Métodos e composições que compreendem variantes de proteína a staphylococcus (spa) |
| WO2021051136A1 (en) | 2019-09-13 | 2021-03-18 | The University Of Chicago | Methods and compositions for treating staphylococcal infections |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0027888B1 (en) * | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| DE3040825A1 (de) | 1980-10-30 | 1982-09-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neues tridekapeptid, verfahren zu seiner herstellung und verwendung |
| US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| JPH0776236B2 (ja) * | 1988-04-13 | 1995-08-16 | 富士写真フイルム株式会社 | 蛋白質修飾物 |
| US5180815A (en) | 1988-04-13 | 1993-01-19 | Fuji Photo Film Co., Ltd. | Modified protein for carrying hapten |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| WO1993015760A1 (en) | 1992-02-11 | 1993-08-19 | U.S. Government, As Represented By The Secretary Of The Army | Dual carrier immunogenic construct |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| DE69433341T2 (de) | 1993-09-22 | 2004-04-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| ATE241384T1 (de) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
| DE69615362T3 (de) | 1995-06-07 | 2006-07-20 | Smithkline Beecham Biologicals S.A. | Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein |
| WO1998026799A1 (en) | 1996-12-18 | 1998-06-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugate vaccine for salmonella paratyphi a |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
| EP1073667A2 (en) * | 1998-04-28 | 2001-02-07 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| KR100642044B1 (ko) | 1999-03-19 | 2006-11-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
| DE20321889U1 (de) | 2002-08-02 | 2012-03-12 | Glaxosmithkline Biologicals S.A. | Impfstoffzusammensetzung |
| US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| JP2008513406A (ja) * | 2004-09-22 | 2008-05-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US9486515B2 (en) * | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US7491517B2 (en) | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
| US7935407B2 (en) * | 2009-02-23 | 2011-05-03 | Tsung-Wei Chen | Decorations |
-
2007
- 2007-01-04 GB GBGB0700136.5A patent/GB0700136D0/en not_active Ceased
-
2008
- 2008-01-02 WO PCT/EP2008/050011 patent/WO2008081014A2/en not_active Ceased
- 2008-01-02 EP EP08707820.0A patent/EP2099487B1/en not_active Not-in-force
- 2008-01-02 JP JP2009544404A patent/JP5683815B2/ja not_active Expired - Fee Related
- 2008-01-02 US US12/521,797 patent/US8858955B2/en not_active Expired - Fee Related
- 2008-01-02 ES ES08707820.0T patent/ES2546186T3/es active Active
- 2008-01-02 CA CA002674007A patent/CA2674007A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514817A5 (enExample) | ||
| RU2402347C2 (ru) | Иммуногенная композиция | |
| Brown et al. | Memory Th1 cells are protective in invasive Staphylococcus aureus infection | |
| Proctor | Challenges for a universal Staphylococcus aureus vaccine | |
| Harro et al. | Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration | |
| Vella et al. | Glycoconjugate vaccines: an update | |
| RU2570730C2 (ru) | Стабильные иммуногенные композиции антигенов staphylococcus aureus | |
| Hwang et al. | Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality | |
| RU2011151781A (ru) | ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus | |
| ES2546186T3 (es) | Procedimiento de fabricación de vacunas | |
| Karauzum et al. | IBT-V02: A multicomponent toxoid vaccine protects against primary and secondary skin infections caused by Staphylococcus aureus | |
| JP2012504660A5 (enExample) | ||
| CN101730543B (zh) | 灭活的葡萄球菌全细胞疫苗 | |
| AU2010280740A1 (en) | Immunogenic composition comprising antigenic S. aureus proteins | |
| CA2739581A1 (en) | Compositions and methods related to bacterial eap, emp, and/or adsa proteins | |
| TW202400225A (zh) | 腦膜炎球菌（Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ）組成物和使用彼之方法 | |
| Mohamed et al. | Vaccine development to prevent Staphylococcus aureus surgical-site infections | |
| O'Hara et al. | Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice | |
| RU2006140958A (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
| US20250206810A1 (en) | Treatment of staphylococcus related diseases | |
| García-Lara et al. | Anti-Staphylococcus aureus immunotherapy: current status and prospects | |
| Scendoni et al. | Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity | |
| Brown | Success and failure of vaccines against renin–angiotensin system components | |
| RU2419628C2 (ru) | Иммуногенная композиция для применения в вакцинации против стафилококков | |
| Wildes et al. | Meningococcal vaccines: a progress report |